The FDA recently approved Afamitresgene autoleucel (afami-cel), an engineered autologous T-cell receptor (TCR) therapy targeting MAGE-A4, a cell surface protein commonly expressed by synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCLS). The gene discussed is MAGEA4; the disease is synovial sarcoma.